NASDAQ: ARQT
Arcutis Biotherapeutics, Inc.
Healthcare · Biotechnology
After hours: $26.60(+0.64%) · as of 7:34 PM ET
Market Cap
$3.31B
52w High
$31.77
52w Low
$13.70
P/E
125.94
Volume
3.23M
Outstanding Shares
125.08M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 72.07% over the last year. Revenue grew 76.11% over the trailing twelve months. Operating margin moved from -32.58% to 7.38%. Free cash flow grew 158.03% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 38th percentile of their historical P/S range.
What would invalidate this read
Operating margin is at 7.38%. Revenue grew 76.11% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
10
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Oct 27, 2026
Q4 FY26 · EPS est $0.05 · Revenue est $134.78M
View